The global mycoplasma testing market covers kits & reagents, services, and instruments used for mycoplasma testing. This market is expected to reach USD 943.4 million by 2022 from USD 523.3 million in 2017, at a CAGR of 12.5%. Increasing growth and government support for pharmaceutical and biotechnology industries, strong R&D investment in life sciences, and cell culture contamination are the major factors driving the growth of the global mycoplasma testing market.
PCR is the fastest growing technique in the market due to its high sensitivity and a low turnaround time. Its application for diverse purposes has opened up a multitude of new possibilities in the field of cell culture. PCR is widely used for the detection of mycoplasma in research and biopharmaceutical production. The detection of mycoplasma using PCR has been considered a more efficient method because it is relatively fast, inexpensive, and not affected by cell culture conditions.
Download PDF Brochure : http://www.marketsandmarkets.com/pdfdownload.asp?id=136509856
Based on products, the mycoplasma testing market is segmented into kits & reagent, services, and instruments. The kits & reagents segment is expected to register the highest CAGR during the forecast period. The need to replenish these consumables more often than instruments and the increasing use of kit-based techniques are the key factors driving the growth of this segment.
On the basis of application, the mycoplasma testing market is segmented into cell line testing, virus testing, end production of cell testing, and other applications. The cell line testing application segment is projected to register the highest growth in this market due to the rapid growth of the biopharmaceutical industry and increasing demand for monoclonal antibodies.
By end user, the mycoplasma testing market is segmented into pharmaceutical & biotechnology companies, contract research organizations, academic research institutes, cell banks, and other end users. The pharmaceutical & biotechnology companies segment accounted for the largest share and is projected to grow at the highest rate as compared to the other segments. Increasing growth in R&D investment in the pharmaceutical industry, increase in the number of biotechnology and pharmaceutical patents granted across the globe are the major factors driving the growth of this segment.
The mycoplasma testing market is classified based on region—North America, Europe, Asia-Pacific, and Rest of the world (RoW). Asia is expected to have the fastest growth rate due to the increase in development and manufacturing of generics, rising household incomes, increased government expenditure on healthcare, higher life expectancies, and consumer health awareness.
The increasing growth of government support for pharmaceutical and biotechnology industries and R&D investments in life sciences across the globe are expected to increase the production of biologics. This will result in the increase in demand for mycoplasma testing. These factors provide the opportunity for market players to generate revenue.
